RE:Canadian Disclosure Law I think you mentioned the PR had too much information and I do think you have a good point.
“A company’s press release should contain enough detail to enable the media and investors to understand the substance and importance of the change it is disclosing.
Companies should be sensitive though to the risks involved in private meetings with analysts. Companies should have a firm policy of providing only non-material information and publicly disclosed information to analysts.”
From PR:
“Efficacy results observed thus far were not convincing enough to pursue enrolling patients and did not outweigh the adverse events seen in some patients.
The current intent for the protocol amendment is to modify the dosage regimen to optimize the delivery of TH1902, with lower doses at more frequent intervals.”
So they said efficacy were not convincing!
Does that mean no efficacy, some efficacy if so where are the details?
And more frequent intervals at lower doses in order to optimize delivery!
Again why they think that would work?
None of these statements have enough details for investors to understand the “substance or importance of the change..”which was the pause and amended protocol.
Again as you said previously posted it had too much information which in my opinion didn’t explain the situation and the rationale behind their decisions.
On private meetings with analysts and large investors we only found out about potential cost cutting from some posters here and the plan about the dosage of 100mg/m2 weekly!
So again in my opinion the PR was not informative enough or had too much unclear information and the analysts and large investors get privileged information which isn’t released publicly.
I am not suggesting they are intentionally breaking the law but the unclear and one sided communication(larger investors)with the market is and has been a major issue which has negatively impacted the demand from smaller investors as you mentioned just the legacy drugs sales justify higher share prices but some investors are confused about the R&D operations and the cost of them/whether it is feasible to move on with them etc.,hopefully their next move will be a clear and well thought strategy presented in timely manner.
palinc2000 wrote: Read this on another MB.Not sure if this is the very latest version but worth reading .... Quite informative as to what and when needs to be disclosed to the market and limits on private discussions with analysts and others (section 5)
https://lautorite.qc.ca/fileadmin/lautorite/reglementation/valeurs-mobilieres/51-201/2001-05-25/2001mai25-51-201-ig-cons-en.pdf